FRS
0.026
160%
OCT
0.045
-42.3%
CRS
0.062
138.5%
NRZ
0.002
-33.3%
AVE
0.007
133.3%
CHM
0.006
-25%
LAT
0.074
111.4%
JAV
0.003
-25%
RLL
0.004
100%
HYD
0.019
-24%
SCN
0.027
80%
DUN
0.033
-23.3%
BP8
0.005
66.7%
TFL
0.01
-23.1%
EVR
0.005
66.7%
EXR
0.034
-22.7%
RGL
0.005
66.7%
GLL
0.007
-22.2%
SLM
0.105
66.7%
OZM
0.125
-21.9%
RR1
0.013
62.5%
TMG
0.036
-21.7%
RAS
0.025
56.3%
AGH
0.02
-20%
BGE
0.03
50%
CRR
0.004
-20%
CDT
0.003
50%
EM2
0.008
-20%
TMK
0.003
50%
CVL
1.06
-19.4%
BSX
0.051
45.7%
NWM
0.013
-18.8%
VIT
0.112
41.8%
AQD
0.04
-18.4%
CMO
0.024
41.2%
BUS
0.155
-18.4%
TOR
0.1
40.8%
LOT
0.195
-17%
EXT
0.018
38.5%
PUA
0.01
-16.7%

4DMedical (ASX:4DX) has signs research agreement

4DMedical (ASX:4DX) has signed a Cooperative Research & Development Agreement with West Los Angeles VA Medical Center for utilisation of 4DMedical’s XV Technology® in the Veteran Affairs Functional Lung Imaging Study.

  • 4DMedical signs Cooperative Research & Development Agreement (CRADA) with West Los Angeles VA Medical Center for utilisation of 4DMedical’s XV Technology® in the Veteran Affairs Functional Lung Imaging Study (VAFLIS)
  • XV Technology® will be used to characterise Veterans with undifferentiated dyspnoea and other respiratory symptoms to determine if changes in treatment pathways are required
  • Announcement follows recent progress at the VA including language in the recent budget and public support from the US Senate
  • Additional sites and increased utilisation builds momentum and support for a large-scale rollout within the VA.

4DMedical MD/CEO and Founder Andreas Fouras said: “4DMedical is targeting success in the VA through a two-pronged approach: top down and bottom up, with the desired outcome being a multi-site pilot leading to a National roll-out. We have discussed recent progress in our top-down efforts, including language in the recent budget and public support from the US Senate. Today we announce yet another bottom-up success with another VA site utilising our technology with the ultimate goal of improving Veteran health. Having VA doctors using our products in this way grows confidence in our solutions and builds momentum and support for a large-scale rollout within the VA.”